Aap Implantate Ag · XETR:AAQ1
Aap Implantate — German Equity Forum 2017
20 slides from Aap Implantate's conference presentation, Nov 29, 2017
Slide 1: aap Implantate AG Corporate Presentation – German Equity Forum 2017
aap Implantate AG Corporate Presentation German Equity Forum 2017 Making Trauma Treatment Bruke Seyoum Alemu, CEO Better and Cost-Effective Marek Hahn, CFO Frankfurt am Main, November 29, 2017
Slide 2: Safe Harbor Statement
Safe Harbor Statement Our publication may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual
Slide 3: aap at a Glance
aap at a Glance Pure player in trauma Orthopedic company focused on trauma addressing unmet needs in trauma surgery: Simplify explantation by avoiding cold-welding Reduce surgical site infections (SSI) caused by implants Avoid second operations by using resorbable metal implants Transformed
Slide 4: Sustainability & Value creation
Our Balanced Portfolio of Innovations Addressing unmet needs and challenges High Incremental innovations Breakthrough innovations Sustainability & Value creation Sell more to existing Reach new customers Shift existing markets Create new market Low customers Impact on market Our source of value crea
Slide 5: Platform Technology – LOQTEQ®
Platform Technology – LOQTEQ® Unmet need / challenge: Simplify explantation by avoiding cold-welding IP-protected Our response: Locking compression technology by aap Angular stable compression in one step Strong clinical evidence of no cold-welding Comprehensive plates and screws portfolio cov
Slide 6: Key Developments Sales 9M/2017
Key Developments Sales 9M/2017 Positive market resonance to our trauma portfolio North America 96% y-o-y sales growth with distributors and remains main growth driver Distribution agreement with global partners signed Germany Growing business with group clinics and purchasing groups (Helio
Slide 7: Surgical Site Infections (SSI)
Surgical Site Infections (SSI) Outlining the market potential for aap’s silver coating technology SSI are burdening global economies enormously “SSI is the most frequent type of health care associated infections (HAI) in low- and middle-income countries affecting up to 1/3 of patients who have u
Slide 8: Platform Technology – Silver Coating
Platform Technology – Silver Coating Unmet need / challenge: Reduce surgical site infections (SSI) caused by implants IP-protected Our response: Antibacterial silver coating by aap Stable coating with high antibacterial efficacy and biocompatibility Cost-effective coating technology Platform t
Slide 9: Platform Technology – Magnesium Implants
Platform Technology – Magnesium Implants Unmet need / challenge: Avoid second operations by using resorbable metal implants IP-protected Our response: Coated Resorbable Magnesium Implant Technology by aap Good biomechanical properties combined with a moderate and controllable resorption rate Cos
Slide 10: LOQTEQ® – Roadmap
LOQTEQ® – Roadmap Addressing unmet needs in trauma through innovations 10
Slide 11: aap – Sum of the Parts
aap – Sum of the Parts Strategic framework of the hidden value Sum of the parts strongly indicates Potential to be first mover in trauma application substantial upside for value creation Wide range of potential applications outside trauma Increasing interest by global companies to partner, Cur
Slide 12: aap’s Equity Story – Pure Player in Trauma
aap’s Equity Story – Pure Player in Trauma Why invest in aap? Making Trauma Treatment Better and Cost-Effective Innovative IP-protected products and platform technologies addressing unmet needs and challenges in trauma LOQTEQ®: Addressing the fastest growing trauma segments Silver Coating: Add
Slide 13: Many thanks for your attention!
Many thanks for your attention! Lorenzweg 5 • 12099 Berlin • Germany Fabian Franke Manager Investor Relations Tel.: +49 30 750 19 – 134 Fax: +49 30 750 19 – 290 E-Mail: ir@aap.de IR-app:
Slide 14: Appendix
Appendix aan
Slide 15: Financial Figures 9M/2017 (1/2)
Financial Figures 9M/2017 (1/2) (in KEUR) Sales 9M/2017 9M/2016 Change Sales (reported) 8,033 8,820 -9% less Q2/2016 initial sales revoked in Q4/2016 0 756 - Sales (like-for-like) 8,033 8,064 N/C Trauma 7,785 6,860 +13% North America 2,414 1,959 +23% DACH 2,036 1,888 +8% Europe w/o DACH 882 1,444 -3
Slide 16: Financial Figures 9M/2017 (2/2)
Financial Figures 9M/2017 (2/2) (in EUR million) Capital Structure 30/09/2017 31/12/2016 Change Total Assets 52.7 63.9 -17% Equity Ratio 84% 86% Cash Flow and investments 9M/2017 9M/2016 Change Operative cash flow -4.4 -5.0 +12% Total investing activities -1.4 -2.0 +29% Cash Structure 30/09/2017 31/
Slide 17: Shareholder Structure
Shareholder Structure (As of 29/11/2017, shareholdings in aap ≥ 3%) High degree of stability with a base of long-term oriented investors Market Cap of approx. EUR 50 million 15.85% Ratio Capital Management B.V., Netherlands Jürgen W. Krebs, Switzerland Noes Beheer B.V., Netherlands 12.50% 42.55%
Slide 18: Notes
Notes cap
Slide 19: Notes
Notes cap
Slide 20: Lorenzweg 5 • 12099 Berlin • Germany Fabian Franke Manager Investor Relations
Lorenzweg 5 • 12099 Berlin • Germany Fabian Franke Manager Investor Relations Tel.: +49 30 750 19 – 134 Fax: +49 30 750 19 – 290 E-Mail: ir@aap.de IR-app: